The research in the Sabatino Laboratory is focused on hemophilia, an inherited bleeding disorder. The interests of the laboratory include the study of variants of coagulation factor VIII to understand the biochemical properties of these proteins and to identify novel variants with enhanced function, and the development of gene-based therapeutic approaches for treating hemophilia.

As director of Clinical Laboratories, Strategic Partnerships and Innovation at the Center for Applied Genomics, Dr. Santani oversees the clinical genomics program for the diagnosis of common and rare genetic disorders.

Dr. Schultz's research involves using magnetic resonance imaging to understand brain mechanisms and to create biomarkers that predict who has autism spectrum disorder (ASD), who will develop the disorder, and who will respond well to different interventions. More recently, he has developed a technology and innovation lab to exploit advances in perceptual computing, in order to develop more robust measurements of quantitative traits.

Dr. Schwartz's research focuses on behavioral and psychosocial aspects of cancer and its treatment in adolescents and young adults (AYAs), a group of patients with unique medical and psychosocial challenges. Most of her current studies aim to understand and improve self-management among AYAs.

Relies on extensive experience in leadership positions in institution, independent, and governmental Institutional Review Boards to support investigators while they navigate multicenter research studies.

Dr. Scribano's areas of interest and research involve the epidemiology and prevention of child maltreatment and intimate partner violence, technology use in healthcare, and health services to children in foster care.

Dr. Seif's research centers on manipulating the human innate and immune systems to treat children with acute lymphoblastic leukemia (ALL). The long-term goal of her research is to identify innate and adaptive immune mechanisms that can be used to treat pediatric ALL more effectively, and with less toxicity, than existing therapies.

Dr. Shah's research is centered on understanding obesity and its related complications. Her current work includes clinical and translational studies exploring pathophysiology and modulation of obesity-related adipose tissue and systemic inflammation using human cell lines and clinical trials. She is also involved in clinical studies of outcomes and risk factors of polycystic ovarian syndrome and type 2 diabetes in teens.

Dr. Shalem’s research focuses on translational target discovery for a range of neurodegenerative diseases. He combines technology development of large-scale CRISPR-based perturbation screens with application of such technology together with additional genomic approaches.

Dr. Shaw is an emergency medicine physician, clinical epidemiologist, and national leader in the fields of pediatric emergency medicine and quality and patient safety. She is most noted for her research in the diagnosis and management of acute pediatric illness and injuries, most notably UTI,
dehydration, and bronchiolitis.

Dr. Silber is the director of the Center for Outcomes Research at CHOP, and is an internationally known authority on outcomes measurement and severity adjustment for both adult and pediatric applications.

Dr. Silverman studies the fundamental aspects of early-life commensal microbes that influence immune system development and function. He discovered that the MHC-II E molecule prevents type 1 diabetes by shaping the intestinal microbiota early in life.

The principal goal of Dr. Simmons' research program is to elucidate the underlying molecular mechanisms that link an aberrant intrauterine milieu to the later development of diseases in adulthood. She has made many seminal contributions to the understanding of the role that epigenetic modifications play in developmental programming of obesity and type 2 diabetes.

Dr. Smith-Whitley's research focuses on sickle cell survivorship: predicting and preventing long-term, chronic, and life-threatening complications of the disease.

Dr. Snyder is a pediatric hematologist oncologist focused on improving the lives of people living with vascular anomalies. She is involved with national and international endeavors to create educational programs and investigational registries, investigate treatments, and author publications in this discipline.

Dr. Song works to elucidate the cellular and molecular basis governing the formation, maintenance, and function of neural circuits under physiological and pathological conditions, using both Drosophila and mammalian models.

Dr. Spergel focuses on translational research in IgE-mediated and non-IgE-mediated food allergy, examining novel clinical methods for desensitization and curing food allergy. His other main projects are to identify predictive factors for severity of reactions using molecular, physiologic, and clinical parameters.

Dr. Spinner's research focuses on the etiology and expressivity of pediatric developmental disorders. She uses genomic methods to focus on the multisystem disorder Alagille syndrome and biliary atresia, a likely heterogeneous and poorly understood condition. She is also interested in using genomic tools to continue to improve diagnostic rates for constitutional genetic disorders.

Vijay Srinivasan, MBBS, MD, works in research and quality improvement programs dealing with critical illness endocrinopathies and nutrition to improve outcomes in critically ill children. His research focuses on stress hyperglycemia with tight glycemic control and nutrition therapy.

Dr. St. Geme's research focuses on bacterial pathogenesis, with an emphasis on defining the molecular and cellular determinants of Haemophilus influenzae and Kingella kingae disease.

Dr. Stallings is working on intervention trials involving three chronic diseases with nutrition-related abnormalities resulting in meaningful adverse outcomes: cystic fibrosis (new drugs), sickle cell disease (vitamin A) and chronic pancreatitis (enzyme replacement drug).

Dr. Stanley’s lab has identified many of the genes and syndromes associated with congenital hyperinsulinism including ABCC8, GCK, GLUD1, and Turner and Beckwith syndromes. Working with clinical and rodent model studies, his lab team has identified distinctive phenotypes of these disorders, including diazoxide unresponsiveness, leucine sensitivity, and protein sensitivity. Dr. Stanley continues to seek new diagnostic and treatment paradigms for infants with acquired and genetic disorders of hyperinsulinism.

Dr. Steenhoff is medical director of the Global Health Center at Children's Hospital. He serves as a global health advocate for children, seeking to optimize mutually beneficial partnerships between clinical and academic institutions in diverse settings.

Effectively builds cross-functional teams that can achieve business and research objectives while assuring optimal animal welfare and regulatory compliance.

Dr. Storm directs CHOP's translational brain tumor laboratory and maintains a research program focusing on cell signaling cascades in pediatric brain tumors. The goal of this research is to understand and identify potential targets that can be developed into clinical therapy. His team is also leading collaborative efforts to de-silo research by engaging in open source platforms and cloud-based sharing.

Dr. Stricker is a clinical outcomes researcher who leads the Pedi-INQUIRE perioperative research team at CHOP. He is a Leonard Davis Institute Senior Fellow, he founded the multicenter Pediatric Craniofacial Collaborative Group, and leads the international Pediatric Perioperative Outcomes Group.

Dr. Sullivan's research focuses on new and rare immunodeficiencies. She has a long-standing interest in one of the most common of the primary immunodeficiencies – chromosome 22q11.2 deletion syndrome. She also investigates common variable immunodeficiency, as well as the genetics and epigenetics of systemic lupus erythematosus.

Promoting collaboration between academia and industry by developing relationships with other institutions, biotechnology, pharmaceutical, and medical device companies to continue research and to commercialize CHOP research discoveries and technology-based ventures.

Dr. Szalda's research focuses on the transition from pediatric to adult care for young adults with medical complexity and cancer survivorship.